Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data presented

  • Promising initial data from MP0250 combination with bortezomib (Velcade®) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer supported by AstraZeneca with free drug supply.
  • Immuno-oncology: DARPin® I/O toolbox established and preclinical data presented at AACR 2018, including MP0310, a FAPx4-1BB multi-DARPin® product candidate.
  • Abicipar: In July 2018, Allergan presented positive phase 3 topline data on abicipar, demonstrating its non-inferiority in a 12-week fixed dosing regimen with less than half the injections vs. Lucentis®; Allergan plans FDA filing in H1 2019 and launch in 2020, while in parallel testing an optimized formulation to reduce inflammation.
  • Oncology expertise further strengthened with Bill Burns elected as Chairman and Pamela A. Trail joining as Chief Scientific Officer.
  • Company well capitalized to capture key value inflection points into 2020 with CHF 122.4 million in cash and short-term deposits as of June 30, 2018. Net cash used in operating activities of CHF 19.4 million in H1 2018, reflecting ongoing build-out of R&D and clinical pipeline.

Media release

back